Concord Biotech Ltd (NSE: CONCORDBIO) and Syngene International Ltd. (NSE: SYNGENE) are both listed in the Pharmaceutical CDMO and CRO Services industry. Concord Biotech has a market capitalisation of ₹12,172 Cr and Syngene International ₹16,439 Cr, as of 9 Nov 2026. Their P/E ratios are 46.7 and 52.5 respectively. Return on equity is 13.54% for Concord Biotech and 6.62% for Syngene International. Over one year, Concord Biotech's share price is down 18.6% and Syngene International's is down 33.7%.
| Metric | Concord Biotech | Syngene International |
|---|---|---|
| NSE Symbol | CONCORDBIO | SYNGENE |
| BSE Code | 543960 | 539268 |
| Share Price | ₹598.40 | ₹436.00 |
| Market Cap | ₹12,172 Cr | ₹16,439 Cr |
| P/E Ratio | 46.7 | 52.5 |
| Return on Equity | 13.54% | 6.62% |
| Return on Assets | 8.91% | 4.78% |
| Dividend Yield | 0.65% | 0.30% |
| Beta (1Y) | 0.17 | -0.08 |
| 1-Year Price Change | -18.6% | -33.7% |
| 3-Month Price Change | -15.7% | +8.3% |
| 52-Week Range | ₹493.50 – ₹807.50 | ₹344.45 – ₹678.95 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹309 Cr | ₹833 Cr |
| Quarterly Net Profit | ₹70 Cr | ₹32 Cr |
| Net Margin | 22.5% | 3.9% |
| EPS (Basic, Quarter) | ₹6.65 | ₹0.80 |
| Results Basis | consolidated | consolidated |
| Headquarters | Ahmedabad, Gujarat | Bengaluru, Karnataka |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinom…
Syngene International Limited, a contract research and manufacturing company, provides drug discovery and development services in India, the United States of America, Europe, and internationally. The company provides discovery chemistry services, such as synthetic and medicinal chemistry, library and peptide synthesis, biomolecular science, organic electronic materials, and computational and analytical chemistry; discovery biology services in the areas of recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK, i…
Syngene International has a market capitalisation of ₹16,439 Cr, against ₹12,172 Cr for Concord Biotech as of 9 Nov 2026, about 1.4 times the size by market cap.
Concord Biotech has a P/E of 46.7 and Syngene International a P/E of 52.5 as of 9 Nov 2026.
Concord Biotech has a return on equity of 13.54% and Syngene International 6.62%.
Concord Biotech's share price is down 18.6% over one year and Syngene International's is down 33.7%.
Concord Biotech reported revenue of ₹309 Cr and net profit of ₹70 Cr for Q2 FY27. Syngene International reported revenue of ₹833 Cr and net profit of ₹32 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.